Selected Projects

Statistical due diligence for a CNS asset for an investors' group.

Statistical support for a mid-size biotech on the clinical program in a rare dermatological disease that included FDA interactions on a sequential design and multiplicity control.

Statistical advice on a design for a phase 2 study in a rare skin disease for a start-up biotech..

Adaptive design for a small biotech's kidney disease study with a different primary endpoint in the US vs. Europe.

Design and statistical analysis plans for two patient registries that are a part of a mid-size biotech's post-marketing commitment to the FDA. Challenges focused on balancing the non-interventional nature of the registries with increasing regulatory requirements including a formal sample size calculations and a stringent statistical analysis.

Eva is currently serving as an independent statistician on two Data Safety and  Monitoring Boards for gene therapy clinical trials ran by a mid-size biotech company.